NAMD Warns Against Broadly Defining Pharmaceutical Value-Based Purchasing in Draft PAVE Act
NAMD wrote to Congress expressing concern with draft legislation that would broadly define pharmaceutical value-based purchasing in a manner that could undermine the Medicaid drug rebate program.
In 2019, Senators Cassidy and Warner introduced the Patient Affordability Value and Efficiency Act, which sought to broadly define pharmaceutical value-based purchasing. In this letter, NAMD warns that such a broad definition would negatively impact fundamental aspects of the Medicaid drug rebate program and increase Medicaid pharmacy benefit spending.
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
Drop us your email and we’ll keep you up-to-date on Medicaid issues.